Blog
RSS FeedPosted by Michael Wonder on 03 Dec 2022
AbbVie announces provincial reimbursement for Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis and psoriatic arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan
1 December 2022 - AbbVie today announced that Rinvoq is now listed as a special authorisation medication or exception medication status ...
Posted by Michael Wonder on 01 Dec 2022
Livtencity (maribavir) receives positive CADTH recommendation for adults with post-transplant cytomegalovirus infection
1 December 2022 - The conditions for the positive recommendation is supported by the findings of the Phase 3 SOLSTICE ...
Posted by Michael Wonder on 01 Dec 2022
Lenvatinib mesylate in combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma
30 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 29 Nov 2022
Capstone announces authorisation of biosimilar human insulin for IV infusion in Canada and EU
29 November 2022 - Capstone announced today that a biosimilar version of human insulin received authorisation from the EMA's CHMP ...
Posted by Michael Wonder on 29 Nov 2022
Health Canada has approved Sotyku (deucravacitinib tablets), an oral treatment for adults with moderate to severe plaque psoriasis
28 November 2022 - Sotyktu is the first and only approved TYK2 inhibitor in Canada and represents an important milestone ...
Posted by Michael Wonder on 26 Nov 2022
GSK Canada submits respiratory syncytial virus vaccine candidate for regulatory review
25 November 2022 - Application includes important pivotal Phase 3 data evaluating the efficacy and safety of our vaccine candidate against ...
Posted by Michael Wonder on 25 Nov 2022
Health Canada authorises Polivy (polatuzumab vedotin) for the first-line treatment of adults with large B-cell lymphoma
24 November 2022 - Authorization is based on pivotal data from the Phase 3 POLARIX trial, which met its primary ...
Posted by Michael Wonder on 24 Nov 2022
Korea to add Canada, Australia to drug pricing reference country list
24 November 2022 - The Government said it would additionally reference Canada and Australia when setting drug prices from January ...
Posted by Michael Wonder on 19 Nov 2022
Novavax’s COVID-19 booster has been approved for adults, Health Canada says
17 November 2022 - Health Canada said Thursday it has approved the booster dose of Novavax‘s Nuvaxovid COVID-19 vaccine for ...
Posted by Michael Wonder on 17 Nov 2022
Canadian migraine sufferers have a new treatment option - Health Canada approves Ubrelvy (ubrogepant)
16 November 2022 - Ubrelvy is the first and only oral CGRP receptor antagonist (gepant) approved by Health Canada for the ...
Posted by Michael Wonder on 11 Nov 2022
CADTH launches consultation on real world evidence reporting guidance
10 November 2022 - Today, CADTH, on behalf of the Real World Evidence Steering Committee, launched a public consultation to ...
Posted by Michael Wonder on 11 Nov 2022
Implementation of the Patented Medicine Prices Review Board's proposed Guidelines will harm Canadian patients
10 November 2022 - Innovative Medicines Canada is calling on Health Canada to direct the Patented Medicine Prices Review Board (PMPRB) ...
Posted by Michael Wonder on 11 Nov 2022
Health Canada approves Camzyos (mavacamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy
10 November 2022 - Camzyos is the only Health Canada approved reversible cardiac myosin inhibitor indicated for the treatment of ...
Posted by Michael Wonder on 07 Nov 2022
Vabysmo (faricimab) receives positive CADTH recommendation for the treatment of diabetic macular oedema in adults
3 November 2022 - This CADTH recommendation is the latest step towards public access to Vabysmo (faricimab) for the estimated 60,000 ...
Posted by Michael Wonder on 07 Nov 2022
New PMPRB guidelines proposed for assessing prices of patented medicines sold in Canada
4 November 2022 - Controversial amendments to the Patented Medicines Regulations changing the basket of comparator countries considered by the ...